A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body’s attack on tumors back into the kind that amplify it. This is the finding of a study led by researchers from NYU Langone Medical Center and published recently in Cancer Immunology Research.
Michelle A. Rudek, a professor of oncology and director of the Analytical Pharmacology Shared Resource at Sidney Kimmel Comprehensive Cancer Center, died Nov. 7. She was 51.Â
